BIOMARIN PHARMACEUTICAL INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $9.50M, a 63.32% decline from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $25.90M, a 19.31% decline from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $32.10M, a 21.13% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2024-12-31 | $9.50M 10-K · filed 2026-02-26 |
| 2023-12-31 | $25.90M 10-K · filed 2026-02-26 |
| 2022-12-31 | $32.10M 10-K · filed 2025-02-24 |
| 2021-12-31 | $40.70M 10-K · filed 2024-02-26 |
| 2020-12-31 | $71.90M 10-K · filed 2023-02-27 |
| 2019-12-31 | $32.50M 10-K · filed 2022-02-25 |
| 2018-12-31 | $79.90M 10-K · filed 2021-02-26 |
| 2017-12-31 | $77.00M 10-K · filed 2020-02-27 |
| 2016-12-31 | $127.40M 10-K · filed 2019-02-28 |
| 2015-12-31 | $146.60M 10-K · filed 2018-02-26 |
| 2014-12-31 | $130.10M 10-K · filed 2017-02-27 |
| 2013-12-31 | $119.20M 10-K · filed 2016-02-29 |
| 2012-12-31 | $94.60M 10-K · filed 2015-03-02 |
| 2011-12-31 | $25.10M 10-K · filed 2014-02-26 |
| 2010-12-31 | $18.00M 10-K · filed 2013-02-26 |
| 2009-12-31 | $4.60M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |